Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multicenter Rollover Study to Provide Continued Treatment With Anetumab Ravtansine for Participants With Solid Tumors Who Were Enrolled in Previous Bayer-sponsored Studies

Next Previous
Trial Profile

An Open-label, Multicenter Rollover Study to Provide Continued Treatment With Anetumab Ravtansine for Participants With Solid Tumors Who Were Enrolled in Previous Bayer-sponsored Studies

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anetumab ravtansine (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Cholangiocarcinoma; Colon cancer; Gastric cancer; Lung cancer; Male breast cancer; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Thymic epithelial tumour
  • Focus Adverse reactions
  • Sponsors Bayer

Most Recent Events

  • 28 Apr 2023 Status changed from completed to discontinued. Due to strategic company decisions, the development of anetumab ravtansine was stopped.
  • 12 Oct 2022 This trial has been Discontinued in Poland, according to European Clinical Trials Database record.
  • 09 Jun 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top